Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Firms Pursued Over Edirol Ingredient

Chugai Files Further Suit Over Eldecalcitol Against Nichi-Iko, Nissan And Sawai

Executive Summary

Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.

You may also be interested in...

Sawai Chalks Up More Than A Dozen Launches

Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.

Eldecalcitol Challenge Filed In Japan

Sawai and Nichi-Iko are in the crosshairs of Chugai after the originator filed a lawsuit in Japan claiming patent infringement over the pair’s generic eldecalcitol versions of its Edirol brand.

Sawai Receives A Host Of Japanese Approvals

Sawai has received a raft of generics approvals from Japan’s Ministry of Health, Labour and Welfare, including approval for a tadalafil rival to Cialis and 10 first-time generic approvals.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts